Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes (INFORM)
Primary Purpose
Atherosclerosis, Leukocyte Activation Disorder, Type 2 Diabetes Mellitus
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
OGTT
Sponsored by
About this trial
This is an interventional diagnostic trial for Atherosclerosis
Eligibility Criteria
Inclusion Criteria:
- Provide written informed consent
- Aged 45-65 years
- BMI < 35 kg/m2
Exclusion Criteria:
- Emotionally and intellectually not capable to decide about participation in the study and the consequences of participation. Subjects who are not able to understand the patient information
- Diabetes mellitus treated with oral antidiabetic medicine
- Type 1 diabetes mellitus
- Peripheral artery and/or coronary disease
- Untreated hypertension
- Alcohol use > 2 units/day
- Aberrations in kidney, liver and thyroid function
- Use of any experimental medication within 6 months of the study
- The use of immunosuppressive drugs
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
T2DM
FCH
FH
Healthy controls
Arm Description
Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization
Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (>1.2 g/L) and elevated triglyceride (TG) levels (>1.7 mmol/L) at the time of diagnosis
Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization
Healthy controls
Outcomes
Primary Outcome Measures
Postprandial change in leukocyte activation
Leukocyte activation is determined by flow cytometry, using fluorescent labelled antibodies: FITC-conjugated anti-CD66b and PE-conjugated anti-CD11b, expressed in mean fluorescence intensity in arbitrary units. The difference in postprandial response, expressed as area under the curve, between patients with T2DM, FCH and healthy controls is determined using ANOVA.
Secondary Outcome Measures
Correlation between chronic glycemia and leukocyte activation
To assess whether chronic hyperglycemia (HbA1c) correlates with postprandial leukocyte activation, correlation between HbA1c and postprandial leukocyte activation (area under the curve) will be determined for the total study group.
Correlation between acute glycemia and leukocyte activation
To assess whether acute hyperglycemia correlates with postprandial leukocyte activation, correlation between fasting glucose levels and postprandial leukocyte activation (area under the curve) will be determined for the total study group.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02130505
Brief Title
Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
Acronym
INFORM
Official Title
Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
June 2007 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
June 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sint Franciscus Gasthuis
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this study, we will investigate both inflammatory systems in healthy volunteers and patients with T2DM on insulin therapy and hyperlipidemia (both familial hyperlipidemia (FH) and familial combined hyperlipidemia (FCH)) during an OGTT.
Detailed Description
Cardiovascular disease (CVD) is number one killer in the Netherlands. Insulin resistance and dyslipideima are the main causes of CVD. Recently, we have shown that there is an acute leukocyte activation after an oral glucose tolerance test (OGTT) in patients with newly-diagnosed diabets mellitus type 2 (T2DM). Leukocyte activation is an important and obligatory aspect in the process of atherosclerosis. Complement system is another important inflammatory component in atherosclerosis, which becomes activated in the postprandial phase.
In this study, we will investigate both inflammatory systems in healthy volunteers and patients with T2DM on insulin therapy and hyperlipidemia (both familial hyperlipidemia (FH) and familial combined hyperlipidemia (FCH)) during an OGTT.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atherosclerosis, Leukocyte Activation Disorder, Type 2 Diabetes Mellitus, Familial Combined Hyperlipidemia
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
51 (Actual)
8. Arms, Groups, and Interventions
Arm Title
T2DM
Arm Type
Active Comparator
Arm Description
Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization
Arm Title
FCH
Arm Type
Active Comparator
Arm Description
Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (>1.2 g/L) and elevated triglyceride (TG) levels (>1.7 mmol/L) at the time of diagnosis
Arm Title
FH
Arm Type
Active Comparator
Arm Description
Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization
Arm Title
Healthy controls
Arm Type
Active Comparator
Arm Description
Healthy controls
Intervention Type
Dietary Supplement
Intervention Name(s)
OGTT
Intervention Description
Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
Primary Outcome Measure Information:
Title
Postprandial change in leukocyte activation
Description
Leukocyte activation is determined by flow cytometry, using fluorescent labelled antibodies: FITC-conjugated anti-CD66b and PE-conjugated anti-CD11b, expressed in mean fluorescence intensity in arbitrary units. The difference in postprandial response, expressed as area under the curve, between patients with T2DM, FCH and healthy controls is determined using ANOVA.
Time Frame
area under the curve during 2 hours
Secondary Outcome Measure Information:
Title
Correlation between chronic glycemia and leukocyte activation
Description
To assess whether chronic hyperglycemia (HbA1c) correlates with postprandial leukocyte activation, correlation between HbA1c and postprandial leukocyte activation (area under the curve) will be determined for the total study group.
Time Frame
area under the curve during 2 hours
Title
Correlation between acute glycemia and leukocyte activation
Description
To assess whether acute hyperglycemia correlates with postprandial leukocyte activation, correlation between fasting glucose levels and postprandial leukocyte activation (area under the curve) will be determined for the total study group.
Time Frame
area under the curve during 2 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Provide written informed consent
Aged 45-65 years
BMI < 35 kg/m2
Exclusion Criteria:
Emotionally and intellectually not capable to decide about participation in the study and the consequences of participation. Subjects who are not able to understand the patient information
Diabetes mellitus treated with oral antidiabetic medicine
Type 1 diabetes mellitus
Peripheral artery and/or coronary disease
Untreated hypertension
Alcohol use > 2 units/day
Aberrations in kidney, liver and thyroid function
Use of any experimental medication within 6 months of the study
The use of immunosuppressive drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manuel Castro Cabezas, MD, PhD
Organizational Affiliation
Sint Franciscus Gasthuis
Official's Role
Study Chair
12. IPD Sharing Statement
Citations:
PubMed Identifier
25456098
Citation
de Vries MA, Alipour A, Klop B, van de Geijn GJ, Janssen HW, Njo TL, van der Meulen N, Rietveld AP, Liem AH, Westerman EM, de Herder WW, Cabezas MC. Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls. Metabolism. 2015 Feb;64(2):213-7. doi: 10.1016/j.metabol.2014.10.011. Epub 2014 Oct 16.
Results Reference
derived
Learn more about this trial
Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
We'll reach out to this number within 24 hrs